JP2007536317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536317A5 JP2007536317A5 JP2007512027A JP2007512027A JP2007536317A5 JP 2007536317 A5 JP2007536317 A5 JP 2007536317A5 JP 2007512027 A JP2007512027 A JP 2007512027A JP 2007512027 A JP2007512027 A JP 2007512027A JP 2007536317 A5 JP2007536317 A5 JP 2007536317A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclohexyl
- dimethylamino
- phenyl
- benzyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 19
- -1 2- (3-Benzoyl-phenyl) -N- [4-dimethylamino-4- (2-fluoro-benzyl) -cyclohexyl] -propionamide 5-oxo-5-phenyl-valeric acid [4-dimethylamino-4 -(2-fluoro-benzyl) -cyclohexyl] -amide Chemical compound 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- VCUSYDGPHVVMDW-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[4-(dimethylamino)-4-phenylcyclohexyl]-4-oxobutanamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1NC(=O)CCC(=O)C1=CC=C(Cl)C=C1 VCUSYDGPHVVMDW-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- QRUCELXGSAWBOY-UHFFFAOYSA-N 2-(3-acetyl-2,2-dimethylcyclobutyl)-N-[4-[(4-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]acetamide Chemical compound C(C)(=O)C1C(C(C1)CC(=O)NC1CCC(CC1)(N(C)C)CC1=CC=C(C=C1)Cl)(C)C QRUCELXGSAWBOY-UHFFFAOYSA-N 0.000 claims description 2
- XKFGLKKOGQNCDA-UHFFFAOYSA-N 2-(3-acetyl-2,2-dimethylcyclobutyl)-n-(4-benzyl-4-piperidin-1-ylcyclohexyl)acetamide Chemical compound CC1(C)C(C(=O)C)CC1CC(=O)NC1CCC(CC=2C=CC=CC=2)(N2CCCCC2)CC1 XKFGLKKOGQNCDA-UHFFFAOYSA-N 0.000 claims description 2
- PBLADULXZGPZEM-UHFFFAOYSA-N 2-(3-acetyl-2,2-dimethylcyclobutyl)-n-[4-(dimethylamino)-4-[(2-fluorophenyl)methyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CC2C(C(C(C)=O)C2)(C)C)CCC1(N(C)C)CC1=CC=CC=C1F PBLADULXZGPZEM-UHFFFAOYSA-N 0.000 claims description 2
- KMGIEOGQXHBWRZ-UHFFFAOYSA-N 2-(3-acetyl-2,2-dimethylcyclobutyl)-n-[4-(dimethylamino)-4-[(3-methylphenyl)methyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CC2C(C(C(C)=O)C2)(C)C)CCC1(N(C)C)CC1=CC=CC(C)=C1 KMGIEOGQXHBWRZ-UHFFFAOYSA-N 0.000 claims description 2
- CGMPDBZLLYKFHT-UHFFFAOYSA-N 2-(3-acetyl-2,2-dimethylcyclobutyl)-n-[4-[(3-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CC2C(C(C(C)=O)C2)(C)C)CCC1(N(C)C)CC1=CC=CC(Cl)=C1 CGMPDBZLLYKFHT-UHFFFAOYSA-N 0.000 claims description 2
- BIVISMFVNZSWFM-UHFFFAOYSA-N 2-(3-acetyl-2,2-dimethylcyclobutyl)-n-[4-benzyl-4-(dimethylamino)cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CC2C(C(C(C)=O)C2)(C)C)CCC1(N(C)C)CC1=CC=CC=C1 BIVISMFVNZSWFM-UHFFFAOYSA-N 0.000 claims description 2
- LBUGDZKZSTZSPU-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-(4-benzyl-4-pyrrolidin-1-ylcyclohexyl)propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N1CCCC1)CC1=CC=CC=C1 LBUGDZKZSTZSPU-UHFFFAOYSA-N 0.000 claims description 2
- AGNBRSNIQDMPLT-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-(4-phenyl-4-piperidin-1-ylcyclohexyl)propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(C=1C=CC=CC=1)N1CCCCC1 AGNBRSNIQDMPLT-UHFFFAOYSA-N 0.000 claims description 2
- OWTRFTYCXTZHNJ-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-[4-(dimethylamino)-4-(2-phenylethyl)cyclohexyl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N(C)C)CCC1=CC=CC=C1 OWTRFTYCXTZHNJ-UHFFFAOYSA-N 0.000 claims description 2
- VYAKFVOLVPXKOM-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-[4-(dimethylamino)-4-[(2-methylphenyl)methyl]cyclohexyl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N(C)C)CC1=CC=CC=C1C VYAKFVOLVPXKOM-UHFFFAOYSA-N 0.000 claims description 2
- NZXXHDHXPVJQQD-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-[4-(dimethylamino)-4-[(3-methylphenyl)methyl]cyclohexyl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N(C)C)CC1=CC=CC(C)=C1 NZXXHDHXPVJQQD-UHFFFAOYSA-N 0.000 claims description 2
- YTOGHMWQACIDSK-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-[4-(dimethylamino)-4-[(4-methylphenyl)methyl]cyclohexyl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N(C)C)CC1=CC=C(C)C=C1 YTOGHMWQACIDSK-UHFFFAOYSA-N 0.000 claims description 2
- VRMJHEJJIQXHJX-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-[4-[(3-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N(C)C)CC1=CC=CC(Cl)=C1 VRMJHEJJIQXHJX-UHFFFAOYSA-N 0.000 claims description 2
- QXDKUFHYJVHZBL-UHFFFAOYSA-N 2-(3-benzoylphenyl)-n-[4-benzyl-4-(dimethylamino)cyclohexyl]propanamide Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)NC(CC1)CCC1(N(C)C)CC1=CC=CC=C1 QXDKUFHYJVHZBL-UHFFFAOYSA-N 0.000 claims description 2
- WCKUHSJENYGSEL-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(4-morpholin-4-yl-4-phenylcyclohexyl)-4-oxobutanamide Chemical compound C1=CC(Cl)=CC=C1C(=O)CCC(=O)NC1CCC(C=2C=CC=CC=2)(N2CCOCC2)CC1 WCKUHSJENYGSEL-UHFFFAOYSA-N 0.000 claims description 2
- XFMIBQVLHKDRJB-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[4-(dimethylamino)-4-[(3-fluorophenyl)methyl]cyclohexyl]-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(Cl)=CC=2)CCC1(N(C)C)CC1=CC=CC(F)=C1 XFMIBQVLHKDRJB-UHFFFAOYSA-N 0.000 claims description 2
- MBJMGSOAYZIFRE-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[4-(dimethylamino)-4-[(4-methylphenyl)methyl]cyclohexyl]-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(Cl)=CC=2)CCC1(N(C)C)CC1=CC=C(C)C=C1 MBJMGSOAYZIFRE-UHFFFAOYSA-N 0.000 claims description 2
- OFXTXOFRRFIADV-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[4-[(2-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(Cl)=CC=2)CCC1(N(C)C)CC1=CC=CC=C1Cl OFXTXOFRRFIADV-UHFFFAOYSA-N 0.000 claims description 2
- IHAGUOIXHBTIPF-UHFFFAOYSA-N 4-(4-fluorophenyl)-4-oxo-n-(4-phenyl-4-piperidin-1-ylcyclohexyl)butanamide Chemical compound C1=CC(F)=CC=C1C(=O)CCC(=O)NC1CCC(C=2C=CC=CC=2)(N2CCCCC2)CC1 IHAGUOIXHBTIPF-UHFFFAOYSA-N 0.000 claims description 2
- ZLNGKMMTTDNAQE-UHFFFAOYSA-N 4-oxo-4-phenyl-n-(4-phenyl-4-piperidin-1-ylcyclohexyl)butanamide Chemical compound C1CC(C=2C=CC=CC=2)(N2CCCCC2)CCC1NC(=O)CCC(=O)C1=CC=CC=C1 ZLNGKMMTTDNAQE-UHFFFAOYSA-N 0.000 claims description 2
- SHKWSBAVRQZYLE-UHFFFAOYSA-N 5-oxo-5-phenylpentanoic acid Chemical compound OC(=O)CCCC(=O)C1=CC=CC=C1 SHKWSBAVRQZYLE-UHFFFAOYSA-N 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010013654 Drug abuse Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- KZDFWALHBNDHDR-UHFFFAOYSA-N N-(4-benzyl-4-piperidin-1-ylcyclohexyl)-4-oxo-4-phenylbutanamide N-[4-(dimethylamino)-4-[(4-methylphenyl)methyl]cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound CN(C)C1(Cc2ccc(C)cc2)CCC(CC1)NC(=O)CCC(=O)c1ccc(F)cc1.O=C(CCC(=O)c1ccccc1)NC1CCC(Cc2ccccc2)(CC1)N1CCCCC1 KZDFWALHBNDHDR-UHFFFAOYSA-N 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 230000037023 motor activity Effects 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- LUMJDZUCCQIHEG-UHFFFAOYSA-N n-(4-benzyl-4-piperidin-1-ylcyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound C1=CC(F)=CC=C1C(=O)CCC(=O)NC1CCC(CC=2C=CC=CC=2)(N2CCCCC2)CC1 LUMJDZUCCQIHEG-UHFFFAOYSA-N 0.000 claims description 2
- RGQDZJZYMFOUCS-UHFFFAOYSA-N n-(4-morpholin-4-yl-4-phenylcyclohexyl)-6-oxoheptanamide Chemical compound C1CC(NC(=O)CCCCC(=O)C)CCC1(C=1C=CC=CC=1)N1CCOCC1 RGQDZJZYMFOUCS-UHFFFAOYSA-N 0.000 claims description 2
- JFKNRQNJJSINFK-UHFFFAOYSA-N n-[4-(dimethylamino)-4-(2-phenylethyl)cyclohexyl]-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1CC(NC(=O)C(=O)C=2C3=CC=CC=C3NC=2)CCC1(N(C)C)CCC1=CC=CC=C1 JFKNRQNJJSINFK-UHFFFAOYSA-N 0.000 claims description 2
- ZSBRUECKKQYGSW-UHFFFAOYSA-N n-[4-(dimethylamino)-4-(2-phenylethyl)cyclohexyl]-4-oxo-4-phenylbutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CCC1=CC=CC=C1 ZSBRUECKKQYGSW-UHFFFAOYSA-N 0.000 claims description 2
- OGWCCMHJLPUJGR-UHFFFAOYSA-N n-[4-(dimethylamino)-4-(2-phenylethyl)cyclohexyl]-5-oxo-5-phenylpentanamide Chemical compound C1CC(NC(=O)CCCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CCC1=CC=CC=C1 OGWCCMHJLPUJGR-UHFFFAOYSA-N 0.000 claims description 2
- NMBWYIGIOCHPFY-UHFFFAOYSA-N n-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1CC(NC(=O)C(=O)C=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC(F)=C1 NMBWYIGIOCHPFY-UHFFFAOYSA-N 0.000 claims description 2
- XWKNYXKXHQRHLE-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(2-fluorophenyl)methyl]cyclohexyl]-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1CC(NC(=O)C(=O)C=2C3=CC=CC=C3NC=2)CCC1(N(C)C)CC1=CC=CC=C1F XWKNYXKXHQRHLE-UHFFFAOYSA-N 0.000 claims description 2
- HLBPWJMKNVREMM-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(2-fluorophenyl)methyl]cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(F)=CC=2)CCC1(N(C)C)CC1=CC=CC=C1F HLBPWJMKNVREMM-UHFFFAOYSA-N 0.000 claims description 2
- IZSLLPPEYGOFJF-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(2-methylphenyl)methyl]cyclohexyl]-4-oxo-4-phenylbutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=CC=C1C IZSLLPPEYGOFJF-UHFFFAOYSA-N 0.000 claims description 2
- WSTAMKONIVHJQP-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(3-fluorophenyl)methyl]cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(F)=CC=2)CCC1(N(C)C)CC1=CC=CC(F)=C1 WSTAMKONIVHJQP-UHFFFAOYSA-N 0.000 claims description 2
- MIMCDTANDFLVIN-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(3-methylphenyl)methyl]cyclohexyl]-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1CC(NC(=O)C(=O)C=2C3=CC=CC=C3NC=2)CCC1(N(C)C)CC1=CC=CC(C)=C1 MIMCDTANDFLVIN-UHFFFAOYSA-N 0.000 claims description 2
- YAMVUYMTYOBGAK-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(3-methylphenyl)methyl]cyclohexyl]-4-oxo-4-phenylbutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=CC(C)=C1 YAMVUYMTYOBGAK-UHFFFAOYSA-N 0.000 claims description 2
- FZUKZMFYJKZBBM-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(4-fluorophenyl)methyl]cyclohexyl]-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1CC(NC(=O)C(=O)C=2C3=CC=CC=C3NC=2)CCC1(N(C)C)CC1=CC=C(F)C=C1 FZUKZMFYJKZBBM-UHFFFAOYSA-N 0.000 claims description 2
- ZSAQIGFEBHYDEX-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(4-fluorophenyl)methyl]cyclohexyl]-4-oxo-4-phenylbutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=C(F)C=C1 ZSAQIGFEBHYDEX-UHFFFAOYSA-N 0.000 claims description 2
- JVAUXRJMHXNGIR-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(4-methylphenyl)methyl]cyclohexyl]-7-oxooctanamide Chemical compound C=1C=C(C)C=CC=1CC1(N(C)C)CCC(NC(=O)CCCCCC(C)=O)CC1 JVAUXRJMHXNGIR-UHFFFAOYSA-N 0.000 claims description 2
- KVBXMQNDDNSVRA-UHFFFAOYSA-N n-[4-(dimethylamino)-4-phenylcyclohexyl]-5-oxo-5-phenylpentanamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1NC(=O)CCCC(=O)C1=CC=CC=C1 KVBXMQNDDNSVRA-UHFFFAOYSA-N 0.000 claims description 2
- SCHWABGSWZDREQ-UHFFFAOYSA-N n-[4-(dimethylamino)-4-phenylcyclohexyl]-5-oxo-5-phenylpentanamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1NC(=O)CCCC(=O)C1=CC=CC=C1 SCHWABGSWZDREQ-UHFFFAOYSA-N 0.000 claims description 2
- ZPQMDFPMMVCQBY-UHFFFAOYSA-N n-[4-(dimethylamino)-4-thiophen-2-ylcyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound C1CC(N(C)C)(C=2SC=CC=2)CCC1NC(=O)CCC(=O)C1=CC=C(F)C=C1 ZPQMDFPMMVCQBY-UHFFFAOYSA-N 0.000 claims description 2
- RHLZKILNPXAJQZ-UHFFFAOYSA-N n-[4-[(2-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1CC(NC(=O)C(=O)C=2C3=CC=CC=C3NC=2)CCC1(N(C)C)CC1=CC=CC=C1Cl RHLZKILNPXAJQZ-UHFFFAOYSA-N 0.000 claims description 2
- CJDZTTYBWFZFJH-UHFFFAOYSA-N n-[4-[(2-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-4-oxo-4-phenylbutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=CC=C1Cl CJDZTTYBWFZFJH-UHFFFAOYSA-N 0.000 claims description 2
- CXRCODHKRPEEJG-UHFFFAOYSA-N n-[4-[(3-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(F)=CC=2)CCC1(N(C)C)CC1=CC=CC(Cl)=C1 CXRCODHKRPEEJG-UHFFFAOYSA-N 0.000 claims description 2
- HAQKLYAYADKHMB-UHFFFAOYSA-N n-[4-[(3-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-5-oxo-5-phenylpentanamide Chemical compound C1CC(NC(=O)CCCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=CC(Cl)=C1 HAQKLYAYADKHMB-UHFFFAOYSA-N 0.000 claims description 2
- ZAEYRIJYCIRNJD-UHFFFAOYSA-N n-[4-[(3-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-6-oxoheptanamide Chemical compound C=1C=CC(Cl)=CC=1CC1(N(C)C)CCC(NC(=O)CCCCC(C)=O)CC1 ZAEYRIJYCIRNJD-UHFFFAOYSA-N 0.000 claims description 2
- HDRSMTFDRVOREL-UHFFFAOYSA-N n-[4-[(4-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-5-oxo-5-phenylpentanamide Chemical compound C1CC(NC(=O)CCCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=C(Cl)C=C1 HDRSMTFDRVOREL-UHFFFAOYSA-N 0.000 claims description 2
- NACRCIBOZBLULL-UHFFFAOYSA-N n-[4-[(4-chlorophenyl)methyl]-4-(dimethylamino)cyclohexyl]-6-oxoheptanamide Chemical compound C=1C=C(Cl)C=CC=1CC1(N(C)C)CCC(NC(=O)CCCCC(C)=O)CC1 NACRCIBOZBLULL-UHFFFAOYSA-N 0.000 claims description 2
- MKGVHMKZVWUFKR-UHFFFAOYSA-N n-[4-benzyl-4-(dimethylamino)cyclohexyl]-4-(4-chlorophenyl)-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(Cl)=CC=2)CCC1(N(C)C)CC1=CC=CC=C1 MKGVHMKZVWUFKR-UHFFFAOYSA-N 0.000 claims description 2
- OHOYASBFQBCRDM-UHFFFAOYSA-N n-[4-benzyl-4-(dimethylamino)cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(F)=CC=2)CCC1(N(C)C)CC1=CC=CC=C1 OHOYASBFQBCRDM-UHFFFAOYSA-N 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 230000001777 nootropic effect Effects 0.000 claims description 2
- 235000015816 nutrient absorption Nutrition 0.000 claims description 2
- 239000000014 opioid analgesic Substances 0.000 claims description 2
- 229940052318 opioid anesthetics Drugs 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 229910052776 Thorium Inorganic materials 0.000 claims 1
- 206010047853 Waxy flexibility Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical class NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- RJOZFODSLXLIQJ-UHFFFAOYSA-N n-[4-(dimethylamino)-4-[(4-methylphenyl)methyl]cyclohexyl]-4-oxo-4-phenylbutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC=CC=2)CCC1(N(C)C)CC1=CC=C(C)C=C1 RJOZFODSLXLIQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- YUALQSSMNCNBMV-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[4-(dimethylamino)-4-[(2-methylphenyl)methyl]cyclohexyl]-4-oxobutanamide Chemical compound C1CC(NC(=O)CCC(=O)C=2C=CC(Cl)=CC=2)CCC1(N(C)C)CC1=CC=CC=C1C YUALQSSMNCNBMV-UHFFFAOYSA-N 0.000 description 1
- LOVVOOWEUPFPNM-UHFFFAOYSA-N CC1=CC=C(CC(CC2)(CCC2C(CC(C2=CC=CC=C2)=O)C(N)=O)N(C)C)C=C1 Chemical compound CC1=CC=C(CC(CC2)(CCC2C(CC(C2=CC=CC=C2)=O)C(N)=O)N(C)C)C=C1 LOVVOOWEUPFPNM-UHFFFAOYSA-N 0.000 description 1
- 0 CN(*)C(*)(CC1)CCC1N Chemical compound CN(*)C(*)(CC1)CCC1N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001598 anti-natriuretic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical class OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004023501A DE102004023501A1 (de) | 2004-05-10 | 2004-05-10 | Oxosubstituierte Cyclohexyl-1,4-diamin-Derivate |
| DE102004023501.5 | 2004-05-10 | ||
| PCT/EP2005/004907 WO2005110970A1 (de) | 2004-05-10 | 2005-05-06 | Oxosubstituierte cyclohexyl-1,4-diamin-derivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007536317A JP2007536317A (ja) | 2007-12-13 |
| JP2007536317A5 true JP2007536317A5 (https=) | 2011-11-24 |
| JP4896009B2 JP4896009B2 (ja) | 2012-03-14 |
Family
ID=34968416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512027A Expired - Fee Related JP4896009B2 (ja) | 2004-05-10 | 2005-05-06 | オキソ置換されたシクロヘキシル−１，４−ジアミンの酸誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7476763B2 (https=) |
| EP (1) | EP1751088B1 (https=) |
| JP (1) | JP4896009B2 (https=) |
| CA (1) | CA2566210C (https=) |
| DE (1) | DE102004023501A1 (https=) |
| WO (1) | WO2005110970A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008110351A2 (en) * | 2007-03-15 | 2008-09-18 | Dompe' Pha.R.Ma S.P.A. | Use of (r) and (s)-2-aryl-propionic acid derivatives as antiseptic agents |
| JP5599774B2 (ja) | 2008-03-27 | 2014-10-01 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ヒドロキシメチルシクロヘキシルアミン類 |
| ATE537143T1 (de) | 2008-03-27 | 2011-12-15 | Gruenenthal Gmbh | Spiro(5.5)undecan derivate |
| PT2260042E (pt) | 2008-03-27 | 2011-12-06 | Gruenenthal Gmbh | Derivados de ciclo-hexano espirocíclicos substituídos |
| WO2009118174A1 (de) | 2008-03-27 | 2009-10-01 | Grünenthal GmbH | Substituierte cyclohexyldiamine |
| CA2719735A1 (en) | 2008-03-27 | 2009-10-01 | Gruenenthal Gmbh | Substituted 4-aminocyclohexane derivatives |
| AU2009228637B2 (en) | 2008-03-27 | 2013-12-19 | Grunenthal Gmbh | (Hetero-)aryl cyclohexane derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304479A (en) | 1991-12-06 | 1994-04-19 | Diagnostic Reagents, Inc. | Phencyclidine compounds and assays for its determination |
| JP2002544223A (ja) * | 1999-05-12 | 2002-12-24 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 精神病性障害の治療方法 |
| FR2797874B1 (fr) * | 1999-08-27 | 2002-03-29 | Adir | Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0012240D0 (en) | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| ES2188344B1 (es) * | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
| DE10123163A1 (de) * | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| US6571525B2 (en) | 2001-08-01 | 2003-06-03 | J. David Coleman | Construction block |
| CA2467337A1 (en) * | 2001-12-21 | 2003-07-10 | H. Lundbeck A/S | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
| US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| DE10252650A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-Harnstoff-Derivate |
| DE10252665A1 (de) | 2002-11-11 | 2004-06-03 | Grünenthal GmbH | 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate |
| DE102004023522A1 (de) * | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Substituierte Cyclohexyl-1,4-diamin-Derivate |
-
2004
- 2004-05-10 DE DE102004023501A patent/DE102004023501A1/de not_active Withdrawn
-
2005
- 2005-05-06 JP JP2007512027A patent/JP4896009B2/ja not_active Expired - Fee Related
- 2005-05-06 CA CA2566210A patent/CA2566210C/en not_active Expired - Fee Related
- 2005-05-06 EP EP05738450.5A patent/EP1751088B1/de not_active Expired - Lifetime
- 2005-05-06 WO PCT/EP2005/004907 patent/WO2005110970A1/de not_active Ceased
-
2006
- 2006-11-09 US US11/594,952 patent/US7476763B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007536321A5 (https=) | ||
| JP2012526061A5 (https=) | ||
| CN1131212C (zh) | 苯基－和吡啶基衍生物 | |
| CN1319529C (zh) | 作为大麻素－cb1受体配体的1h－1,2,4－三唑－3－酰胺衍生物 | |
| RU2003134147A (ru) | Замещенные производные циклогексан-1,4-диамина | |
| JP2007536317A5 (https=) | ||
| CN1882581A (zh) | N－[杂芳基(哌啶－2－基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用 | |
| JP2004509162A (ja) | アミノアルコール誘導体 | |
| RU2498982C2 (ru) | Новые лиганды ванилоидных рецепторов и их применение для изготовления лекарственных средств | |
| JP2005527492A5 (https=) | ||
| RU2004137091A (ru) | Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора | |
| CN1498104A (zh) | 肽类化合物用于治疗异常性疼痛或其他不同类慢性痛或幻痛的新应用 | |
| JP2009543825A5 (https=) | ||
| JP2010510202A5 (https=) | ||
| CA2660529A1 (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| CN1180352A (zh) | 新颖的芳基甘氨酰胺衍生物,其制造方法及含该化合物的药物组合物 | |
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| CN1192199A (zh) | 2－(4－取代)－苄基氨基－2－甲基－丙酰胺衍生物 | |
| FI3956310T3 (fi) | Modifioituja aminohappojohdannaisia neurologisten sairauksien ja valittujen psykiatristen häiriöiden hoitamiseksi | |
| EP2260022A1 (de) | Substituierte cyclohexyldiamine | |
| JP2024540030A (ja) | 修飾インドール化合物 | |
| JP2007536320A5 (https=) | ||
| EP1560809A1 (de) | Cyclohexyl-harnstoff-derivate | |
| JP2007536321A (ja) | ヘテロアリール−置換されたシクロヘキシル−１，４−ジアミン誘導体 | |
| JP2007536319A5 (https=) |